Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. .TMU Publications / 北醫出版品(教師升等著作 / 教學實踐 / 學位論文)
  3. .博碩士學位論文
  4. 108學年度
  5. 利用三功能抗體武裝甲氧基聚乙二醇修飾之奈米藥物以治療富含纖維母細胞之實體腫瘤
 
  • Details
Options

利用三功能抗體武裝甲氧基聚乙二醇修飾之奈米藥物以治療富含纖維母細胞之實體腫瘤

Other Title
Arming mPEGylated Nanomedicines with Tri-Specific Antibodies to Eliminate Fibroblasts-Surrounding Solid Tumors
Type
thesis
Date Issued
2020-07-08
Author(s)
陳挺宇
Advisor
莊國祥
Subjects
系所名稱:中草藥臨床藥物研發博士學位學程
Description
學位別:博士
語文別:英文
指導教授:莊國祥
口試委員:卓爾婕 Er-Chieh Cho;鄒協成 Shey-Cherng Tzou;鄭添祿 Tain-Lu Cheng
電子論文連結:https://handle.ncl.edu.tw/11296/8885e7
URI
https://203.71.86.71/handle/123456789/61242

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback